EP300 and idiopathic pulmonary fibrosis: Taken together, the results from this very interesting study support a key role of active p300 and Class I HDAC inactivation during IPF and propose p300 inhibition as therapy for IPF, but stands in vast contrast to numerous reports suggesting HDAC inhibitors for targeting increased Class I HDAC activity in fibrotic fibroblasts as a therapeutic option for IPF patients.